<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01866033</url>
  </required_header>
  <id_info>
    <org_study_id>CR101359</org_study_id>
    <secondary_id>PCI-32765CLL1011</secondary_id>
    <secondary_id>2013-000963-96</secondary_id>
    <nct_id>NCT01866033</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Absolute Bioavailability of Oral PCI-32765 and the Effect of Grapefruit Juice on the Bioavailability of PCI-32765 in Healthy Participants</brief_title>
  <official_title>An Open-Label, Sequential and 2-Way Crossover Pharmacokinetic Study to Assess the Absolute Bioavailability of Oral PCI-32765 and the Effect of Grapefruit Juice on the Bioavailability of PCI-32765 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pharmacyclics LLC.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the absolute bioavailability of oral PCI-32765 and the&#xD;
      effect of grapefruit juice on the absorption of PCI-32765 in healthy adult participants.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label (identity of assigned study drug will be known), sequential and 2-way&#xD;
      crossover design, pharmacokinetic (study of what the body does to a drug) study to assess the&#xD;
      absolute bioavailability of oral (by mouth) PCI-32765 and the effect of grapefruit juice on&#xD;
      the absorption of PCI-32765 in approximately 8 healthy adult participants. The duration of&#xD;
      the study is approximately 45 days (screening, treatment, and follow-up). All patients will&#xD;
      receive PCI-32765 560 mg (Treatment A) administered by mouth in the first period and&#xD;
      Treatment B (560 mg administered by mouth without grapefruit juice) and Treatment C (140 mg&#xD;
      administered by mouth with grapefruit juice) according to a randomization schedule in Periods&#xD;
      2 and 3. Participants will fast overnight for at least 10 hours prior to study drug dosing.&#xD;
      Participants will stay in the study center for pharmacokinetic sampling. Serial&#xD;
      pharmacokinetic samples will be collected before dosing and over 72 hours after dosing and&#xD;
      safety will be monitored throughout the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve from time 0 to 24 hours of PCI-32765</measure>
    <time_frame>Predose, and postdose at 30 min, 1 h, 1.5 h, 2 h, 2 h 2 min, 2 h 5 min, 2.2 h, 2.25 h, 2.5 h, 3 h, 3.5 h, 4 h, 5 h, 6 h, 8 h, 12 h, 16 h, 24 h, 36 h, 48 h, 72 h</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve from time 0 to time of the last quantifiable concentration of PCI-32765</measure>
    <time_frame>Predose, and postdose at 30 min, 1 h, 1.5 h, 2 h, 2 h 2 min, 2 h 5 min, 2.2 h, 2.25 h, 2.5 h, 3 h, 3.5 h, 4 h, 5 h, 6 h, 8 h, 12 h, 16 h, 24 h, 36 h, 48 h, 72 h</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve from time 0 to infinite time of PCI-32765</measure>
    <time_frame>Predose, and postdose at 30 min, 1 h, 1.5 h, 2 h, 2 h 2 min, 2 h 5 min, 2.2 h, 2.25 h, 2.5 h, 3 h, 3.5 h, 4 h, 5 h, 6 h, 8 h, 12 h, 16 h, 24 h, 36 h, 48 h, 72 h</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Absolute bioavailability of PCI-32765</measure>
    <time_frame>Predose, and postdose at 30 min, 1 h, 1.5 h, 2 h, 2 h 2 min, 2 h 5 min, 2.2 h, 2.25 h, 2.5 h, 3 h, 3.5 h, 4 h, 5 h, 6 h, 8 h, 12 h, 16 h, 24 h, 36 h, 48 h, 72 h</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration of PCI-32765</measure>
    <time_frame>Predose, and postdose at 30 min, 1 h, 1.5 h, 2 h, 2 h 2 min, 2 h 5 min, 2.2 h, 2.25 h, 2.5 h, 3 h, 3.5 h, 4 h, 5 h, 6 h, 8 h, 12 h, 16 h, 24 h, 36 h, 48 h, 72 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach the maximum plasma concentration of PCI-32765</measure>
    <time_frame>Predose, and postdose at 30 min, 1 h, 1.5 h, 2 h, 2 h 2 min, 2 h 5 min, 2.2 h, 2.25 h, 2.5 h, 3 h, 3.5 h, 4 h, 5 h, 6 h, 8 h, 12 h, 16 h, 24 h, 36 h, 48 h, 72 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination half-life of PCI-32765</measure>
    <time_frame>Predose, and postdose at 30 min, 1 h, 1.5 h, 2 h, 2 h 2 min, 2 h 5 min, 2.2 h, 2.25 h, 2.5 h, 3 h, 3.5 h, 4 h, 5 h, 6 h, 8 h, 12 h, 16 h, 24 h, 36 h, 48 h, 72 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants affected by an adverse event</measure>
    <time_frame>Up to 30 days after the last dose of study medication</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>PCI-32765</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During Period 1, all patients will receive PCI-32765 560 mg administered by mouth (Treatment A). In Periods 2 and 3, patients will receive PCI-32765 560 mg administered by mouth without grapefruit juice (Treatment B) and PCI-32765 140 mg administered by mouth with grapefruit juice (Treatment C) according to a randomization schedule. An intravenous dose of 13C6 PCI-32765 will be administered 2 hours after each oral dose for reference purposes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PCI-32765 (Treatment A)</intervention_name>
    <description>560 mg capsules administered by mouth on Day 1, Period 1</description>
    <arm_group_label>PCI-32765</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PCI-32765 (Treatment B)</intervention_name>
    <description>560 mg capsules administered by mouth (without grapefruit juice) on Day 1 during Period 2 or 3 according to randomization schedule</description>
    <arm_group_label>PCI-32765</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PCI-32765 (Treatment C)</intervention_name>
    <description>140 mg capsule administered by mouth (with grapefruit juice) on Day 1 during Period 2 or 3 according to randomization schedule</description>
    <arm_group_label>PCI-32765</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>13C6 PCI-32765 (reference)</intervention_name>
    <description>100 mcg administered intravenously 2 h after study drug</description>
    <arm_group_label>PCI-32765</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women must be postmenopausal or surgically sterile&#xD;
&#xD;
          -  Men must agree to use an adequate contraception method during the study and for 3&#xD;
             months after receiving the last dose of study drug, and to not donate sperm during the&#xD;
             study and for 3 months after receiving the last dose of study drug&#xD;
&#xD;
          -  Body mass index between 18 and 30 kg/m2 and body weight not less than 50 kg&#xD;
&#xD;
          -  Blood pressure (after lying down for 5 minutes) between 90 and 140 mmHg systolic and&#xD;
             no higher than 90 mmHg diastolic&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of or current clinically significant medical illness including (but not&#xD;
             limited to) cardiac arrhythmias or other cardiac disease, hematologic disease,&#xD;
             coagulation disorders (including any abnormal bleeding or blood dyscrasias), lipid&#xD;
             abnormalities, significant pulmonary disease, including bronchospastic respiratory&#xD;
             disease, diabetes mellitus, renal or hepatic insufficiency, thyroid disease,&#xD;
             neurologic or psychiatric disease, infection, history of immune disorders (eg, lupus,&#xD;
             rheumatoid arthritis, psoriatic arthritis), or any other illness that the investigator&#xD;
             considers should exclude the participant or that could interfere with the&#xD;
             interpretation of the study results&#xD;
&#xD;
          -  Clinically significant abnormal values for hematology, coagulation, PFA 100, clinical&#xD;
             chemistry, or urinalysis at screening&#xD;
&#xD;
          -  Clinically significant abnormal physical examination, vital signs, or 12 lead&#xD;
             electrocardiogram at screening&#xD;
&#xD;
          -  Use of aspirin, NSAIDs, thienopyridines, vitamin E supplements, fish oil, or flax seed&#xD;
             within 1 week before PFA-100 assay test at screening&#xD;
&#xD;
          -  Use of any prescription or nonprescription medication (including vitamins and herbal&#xD;
             supplements), except for paracetamol, hormonal replacement therapy and topical&#xD;
             anesthetics (intravenous administration), within 14 days before the first dose of the&#xD;
             study drug is scheduled&#xD;
&#xD;
          -  Use of herbal supplements within 30 days of the first dose administration&#xD;
&#xD;
          -  History of drug or alcohol abuse according to the Diagnostic and Statistical Manual of&#xD;
             Mental Disorders (4th edition) (DSM-IV) criteria within 2 years before screening or&#xD;
             positive test result(s) for alcohol and/or drugs of abuse at screening and Day -1 of&#xD;
             each treatment period&#xD;
&#xD;
          -  History of clinically significant allergies, especially known hypersensitivity or&#xD;
             intolerance to sulfonamide or beta-lactam antibiotics&#xD;
&#xD;
          -  Known allergy to the study drug or any of the excipients of the formulation&#xD;
&#xD;
          -  Donated blood or blood products or had substantial loss of blood (more than 500 mL)&#xD;
             within 3 months before the first administration of study drug or intention to donate&#xD;
             blood or blood products during the study&#xD;
&#xD;
          -  Received an experimental drug or used an experimental medical device within 1 month or&#xD;
             within a period less than 10 times the drug's half life, whichever is longer, before&#xD;
             the first dose of the study drug is scheduled&#xD;
&#xD;
          -  Unable to swallow solid, oral dosage forms whole with the aid of water&#xD;
&#xD;
          -  If a woman, pregnant, breast-feeding or planning to become pregnant during the study&#xD;
&#xD;
          -  Positive test for human immunodeficiency virus 1 and 2 antibodies, hepatitis B surface&#xD;
             antigen, or hepatitis C antibodies&#xD;
&#xD;
          -  History of smoking or use of nicotine-containing substances within the previous 2&#xD;
             months or positive cotinine test&#xD;
&#xD;
          -  Preplanned surgery or procedures that would interfere with the conduct of the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Merksem</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <study_first_submitted>May 28, 2013</study_first_submitted>
  <study_first_submitted_qc>May 28, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 31, 2013</study_first_posted>
  <last_update_submitted>March 16, 2014</last_update_submitted>
  <last_update_submitted_qc>March 16, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 18, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy volunteer</keyword>
  <keyword>PCI-32765</keyword>
  <keyword>PCI 45227</keyword>
  <keyword>13C6 PCI-32765</keyword>
  <keyword>Pharmacokinetic</keyword>
  <keyword>Bioavailability</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

